The immune response consists of a finely-tuned program, the activation of which must be
coupled with inhibitory mechanisms whenever initiated. This ensures tight control of …

Hypoxia is a known feature of solid tumors and a critical promoter of tumor hallmarks.
Hypoxia influences tumor immunity in a way favoring immune evasion and resistance …

Hepatocellular carcinoma (HCC) has high relapse and low 5-year survival rates. Single-cell
profiling in relapsed HCC may aid in the design of effective anticancer therapies, including …

Due to their autosynchronous roles in shaping the anti-tumor immune response, complex
immune regulatory networks acting both locally within the tumor microenvironment as well …

Tumor-infiltrating B cells (TIL-B) in breast cancer (BC) have previously been associated with
improved clinical outcomes; however, their roles in tumor immunity are not currently well …

CD8+ T cells are the front-line defensive cells against cancer. Reduced infiltration and
effector function of CD8+ T cells occurs in cancer and is contributed to defective immunity …

Immunotherapy has shown promising results in cancer treatment. Research shows that most
patients might be resistant to these therapies. So, new immune therapies are needed. OX40 …

Despite nearly 30 years of development and recent highlights of nitric oxide (NO) donors
and NO delivery systems in anticancer therapy, the limited understanding of exogenous …

The progression of breast cancer and its association with clinical outcome and treatment
remain largely unexplored. Accumulating data has highlighted the interaction between cells …

Breast cancer has been shown to be resistant to immunotherapies. To overcome this
challenge, we developed an active immunotherapy for personalized treatment based on a …